Literature DB >> 1490490

Solid-phase extraction of piribedil and its metabolites from plasma and urine without and after deconjugation, by high performance liquid chromatography.

S Sarati1, S Caccia.   

Abstract

A new high performance liquid chromatographic procedure has been developed for the simultaneous quantification of piribedil (PD) and its three main basic metabolites in rat plasma and urine, without and after hydrolysis. The procedure relies on isolation of the compounds from plasma and urine constituents using the Sep-Pak C18 cartridge, with satisfactory recovery and specificity, and resolution by acetonitrile gradient elution on a C18 reversed phase column coupled to a UV detector monitored at 240 nm. The assay was linear over a wide range of concentrations for all compounds in both body fluids with mean within-day and day-to-day coefficient of variation (CV) and relative error (RE) generally below 10%. Plasma concentrations of PD and its metabolites at selected intervals and urinary recoveries of all compounds before and after enzymatic hydrolysis are presented.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1490490     DOI: 10.1007/BF03190147

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  Levels of piribedil and its active metabolite (S-584) in the rat striatum.

Authors:  R Fanelli; A Frigerio; S Garattini
Journal:  Xenobiotica       Date:  1975-10       Impact factor: 1.908

2.  Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography.

Authors:  S Sarati; G Guiso; R Spinelli; S Caccia
Journal:  J Chromatogr       Date:  1991-02-15

3.  Stimulation of a dopamine-sensitive adenylate cyclase in homogenates of rat striatum by a metabolite of piribedil (ET 495).

Authors:  R J Miller; L L Iversen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

4.  Piribedil: behavioural, neurochemical and clinical profile of a dopamine agonist.

Authors:  C T Dourish
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1983       Impact factor: 5.067

5.  Letter: Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent.

Authors:  P Jenner; A R Taylor; D B Campbell
Journal:  J Pharm Pharmacol       Date:  1973-09       Impact factor: 3.765

6.  Dopamine agonist and antagonist activities of piribedil (ET495)and its metabolites.

Authors:  B Costall; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

7.  Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats.

Authors:  S Sarati; G Guiso; S Garattini; S Caccia
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584.

Authors:  I Creese
Journal:  Eur J Pharmacol       Date:  1974-09       Impact factor: 4.432

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.